Arcturus Therapeutics (ARCT) News
NASDAQ: ARCTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
7.45-0.15 (-1.97%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ARCT news summary
We found 5 recent headlines mentioning Arcturus Therapeutics (ARCT): 1 in the past week and 5 in the past 30 days, most often from Nasdaq, Business Wire. For price context, ARCT is down 1.97% at $7.45. The most recent story, "Arcturus Therapeutics Holdings Inc. Sells 2,466,395 Shares of Common Stock to Meiji Seika Pharma Co., Ltd. for $50.0 million", was published by Nasdaq on Nov 16, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Arcturus Therapeutics headlines
- Arcturus Therapeutics Holdings Inc. Sells 2,466,395 Shares of Common Stock to Meiji Seika Pharma Co., Ltd. for $50.0 millionArcturus Therapeutics Holdings Inc. entered into a Securities Purchase Agreement on November 16, 2026, with Meiji Seika Pharma Co., Ltd. under which the company sold 2,466,395 shares of common stock…Nasdaq
- Arcturus Therapeutics Announces Third Quarter 2026 Financial Results and Pipeline ProgressArcturus Therapeutics Holdings Inc. reported its financial results for the third quarter ended September 30, 2026. Revenue was $18.3 million and $23.3 million for the three and nine months ended…Nasdaq
- Arcturus (ARCT) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The MoNasdaqARCT, UHAL.B
- Arcturus Therapeutics Announces Third Quarter 2026 Financial Results and Pipeline ProgressSAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and…Business Wire
- Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 5, 2026SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and…Business Wire